Table 3.

Radiation exposure during ERCP

	Phase I		Phase II		Phase I vs. Phase II
	Median	IQR	Median	IQR	% reduction	P value
FT (min)
HVE	6.4	5.5 – 8.3	3.3	1.7 – 5.5	48	<0.0001
LVE	5.4	3.5 – 7.1	3.8	2.3 – 5.9	30	<0.001
Total Dose (mGy)
HVE	42.9	42.9 – 125.1	53.1	27.9 – 98.8	−28	<0.0001
LVE	98.3	56.4 – 189.9	46.9	28.6 – 95.5	52	<0.001
DAP (Gy-cm2)
HVE	8.8	5.3 – 14.4	5.7	2.9 – 10.1	35	<0.0001
LVE	13.9	8.8 – 23.1	7.2	4.2 – 9.9	48	<0.0001
ED (mSv)
HVE	2.3	1.4 – 3.7	1.5	0.8 – 2.6	35	<0.0001
LVE	3.6	2.3 – 6.0	1.9	1.1 – 2.6	48	<0.0001
	HVE		LVE		HVE vs. LVE
	Median	IQR	Median	IQR	% reduction	P value
FT (min)
Phase I	6.4	5.5 – 8.3	5.4	3.5 – 7.1	15	<0.0001
Phase II	3.3	1.7 – 5.5	3.8	2.3 – 5.9	13	0.363
Total Dose (mGy)
Phase I	74.1	43.0 – 125.1	98.3	56.4 – 189.9	33	<0.0001
Phase II	53.1	27.9 – 98.8	46.9	28.6 – 95.5	11	0.545
DAP (Gy-cm2)
Phase I	8.8	5.3 – 14.4	13.9	8.8 – 23.1	59	<0.0001
Phase II	5.7	2.9 – 10.1	7.2	4.2 – 9.9	26	0.465
ED (mSv)
Phase I	2.3	1.4 – 3.8	3.6	2.3 – 6.0	59	<0.0001
Phase II	1.5	0.8 – 2.6	1.9	1.1 – 2.6	26	0.465